Fecal biomarkers in inflammatory bowel disease: how, when and why?

References

• Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990 Apr;98(4):811–818.
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut. 1994 Feb;35(2):231–235.
   PubMed Web of Science ®Google Scholar
• Jones J, Loftus EV, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 2008 Nov;6(11):1218–1224.
   PubMed Web of Science ®Google Scholar
• Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001 Jan;120(1):13–20.
   PubMed Web of Science ®Google Scholar
• Linskens RK, Van Bodegraven AA, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig. Dis. Sci. 2001 Mar;46(3):644–648.
   PubMed Web of Science ®Google Scholar
• Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn’s colitis. Scand. J. Gastroenterol. 1995 Apr;30(4):356–360.
   PubMed Web of Science ®Google Scholar
• Schunk K, Kern A, Oberholzer K, et al. Hydro-MRI in Crohn’s disease: appraisal of disease activity. Invest. Radiol. 2000 Jul;35(7):431–437.
   PubMed Web of Science ®Google Scholar
• Gomes P, Du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986 Jan;27(1):92–95.
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis. 2005 Aug;11(8):707–712.
   PubMed Web of Science ®Google Scholar
• Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis. Colon Rectum. 2008 Aug;51(8):1283–1291.
   PubMed Web of Science ®Google Scholar
• Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull. Eur. Physiopathol. Respir. 1980;16(Suppl):273–282.
   PubMedGoogle Scholar
• Guerrant RL, Araujo V, Soares E, et al. “Measurement of fecal lactoferrin as a marker of fecal leukocytes”. J. Clin. Microbiol. 1992 May;30(5):1238–1242.
   PubMed Web of Science ®Google Scholar
• Foell D, Frosch M, Sorg C, et al. Foell. Clin. Chim. Acta. 2004;344(1):37–51.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2002 Apr;16(4):675–681.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 1992 Sep;27(9):793–798.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1999 Jan;34(1):50–54.
   PubMed Web of Science ®Google Scholar
• Wassell J, Wallage M, Brewer E. Evaluation of the quantum blue® rapid test for faecal calprotectin. Ann. Clin. Biochem. 2012 Jan;49(1):55–58.
   PubMed Web of Science ®Google Scholar
• Kok L, Elias SG, Witteman BJM, et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the cost-effectiveness of a decision rule for abdominal complaints in primary care (CEDAR) Study. Clin. Chem.. 2012;58:6.
   PubMed Web of Science ®Google Scholar
• Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J. Crohn’s Colitis. 2012;6:207–214.
   Google Scholar
• Kolho KL, Turner D, Veereman-Wauters G, et al. Rapid test for fecal calprotectin levels in children with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2012 Oct;55(4):436–439.
   PubMed Web of Science ®Google Scholar
• Angriman I, Scarpa M, D’Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin. Chim. Acta. 2007;381(1):63–68.
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Hellström PM, Fagerhol MK, et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005 Feb;2(2):96–102.
   PubMedGoogle Scholar
• Manceau H, Chicha-Cattoir V, Puy H, et al. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin. Chem. Lab. Med. 2016 Sep. doi: 10.1515/cclm-2016-0522.
   PubMed Web of Science ®Google Scholar
• Lopez RN, Leach ST, Lemberg DA, et al. Faecal biomarkers in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2016. doi: 10.1111/jgh.13611.
   Web of Science ®Google Scholar
• Miranda LP, Tao T, Jones A, et al. Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett. 2001 Jan;488(1–2):85–90.
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 2007 Jul;3(7):382–390.
   PubMedGoogle Scholar
• Rendek Z, Falk M, Grodzinsky E, et al. Effect of oral diclofenac intake on faecal calprotectin. Scand. J. Gastroenterol. 2016 Jan;51(1):28–32.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Clark A, Walkden A, et al. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years. J. Crohns. Colitis. 2015 Jan;9(1):41–49.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Pantaleoni S, Touscoz GA, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand. J. Gastroenterol.. 2014 Dec;49(12):1419–1424.
   PubMed Web of Science ®Google Scholar
• Van Rheenen PF, Van De Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010 Jul;341:c3369.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm. Bowel Dis. 2014 Apr;20(4):742–756.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2010 Jun;4(3):285–291.
   PubMed Web of Science ®Google Scholar
• Iacucci M, Ghosh S. Mucosal healing - how deep is enough? Dig. Dis. 2016;34(1–2):160–164.
   PubMed Web of Science ®Google Scholar
• Levay P, Viljoen M. Lactoferrin: a general review. Haematologica. 1995;80:252–267.
   PubMed Web of Science ®Google Scholar
• Dai J, Liu W-Z, Zhao Y-P, et al. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand. J. Gastroenterol. 2007 Jan;42(12):1440–1444.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment. Pharmacol. Ther. 2008;28(10):1221–1229.
   PubMed Web of Science ®Google Scholar
• Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J. Crohns. Colitis. 2013 Dec;7(12):e641–51.
   PubMedGoogle Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am. J. Gastroenterol. 2012;108(1):83–89.
   PubMed Web of Science ®Google Scholar
• Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am. J. Gastroenterol. 2015 Jun;110(6):873–880.
   PubMed Web of Science ®Google Scholar
• Kato J, Hiraoka S, Nakarai A, et al. Fecal immunochemical test as a biomarker for inflammatory bowel diseases : can it rival fecal calprotectin. Intest Res. 2016;14(1):5–14.
   Google Scholar
• Frin A-C, Filippi J, Boschetti G, et al. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis. 2017 Jan;49(1):11-16.
   PubMedGoogle Scholar
• Pallone F, Vitali R, Cucchiara S, et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2014 Aug;20(8):1448–1457.
   PubMed Web of Science ®Google Scholar
• Pallone F, Vitali R, Mennini M, et al. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease who are in clinical and endoscopic remission. Dig. Liver Dis. 2016;48:e264.
   Google Scholar
• Thorsvik S, Damås JK, van Beelen Granlund A, et al. Fecal neutrophil gelatinase associated lipocalin (NGAL) as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol. 2017 Jan;32(1):128-135.
   PubMed Web of Science ®Google Scholar
• Shaw C, Spies P, Ueberschlag M-E, et al. Tu1939 performance testing of ibdoc®, a novel smartphone-based monitoring system for measuring fecal calprotectin: comparison to ELISA rapid test. Gastroenterology. 2016 Apr;150(4):S984.
   Web of Science ®Google Scholar
• Mirsepasi-Lauridsen HC, Bachmann Holmetoft U, Ingdam Halkjær S, et al. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2016 Feb;51(2):211–217.
   PubMed Web of Science ®Google Scholar
• Jang HW, Kim HS, Park SJ, et al. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest. Res. 2016;14(4):305–313.
   PubMed Web of Science ®Google Scholar
• Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones—a new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2016 Feb;22(2):336–344.
   PubMed Web of Science ®Google Scholar
• Amcoff K, Stridsberg M, Lampinen M, et al. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol. 2017 Mar;52(3):344-350.
   Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm. Bowel Dis. 2009 Nov;15(11):1746–1754.
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer P-O, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn’s Colitis. 2015 Jan;9(1):26-32.
   Google Scholar
• Kristensen V, Malmstrøm GH, Skar V, et al. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand. J. Gastroenterol. 2016 May;51(5):548–555.
   PubMed Web of Science ®Google Scholar
• Kostakis ID, Cholidou KG, Vaiopoulos AG, et al. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review. Dig. Dis. Sci. 2013 Feb;58(2):309–319.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Li F, Wang J, et al. Fecal calprotectin in healthy children aged 1-4 years. PLoS One. 2016;11(3):1–10.
   Web of Science ®Google Scholar
• Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2004;13:279–284.
   PubMed Web of Science ®Google Scholar
• Licata A, Randazzo C, Cappello M, et al. Fecal calprotectin in clinical practice. J. Clin. Gastroenterol. 2012 Jul;46(6):504–508.
   PubMed Web of Science ®Google Scholar
• Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of c-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol. 2015 Mar;110(3):444–454.
   PubMed Web of Science ®Google Scholar
• von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol. 2007 Apr;102(4):803–813.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am. J. Gastroenterol. 2015 Jun;110(6):802–819.
   PubMed Web of Science ®Google Scholar
• Ricanek P, Brackmann S, Perminow G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand. J. Gastroenterol. 2011 Sep;46(9):1081–1091.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010 Jan;105(1):162–169.
   PubMed Web of Science ®Google Scholar
• Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. 2016;16(1):47.
   PubMed Web of Science ®Google Scholar
• Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 2016 May;22(5):1042–1048.
   PubMed Web of Science ®Google Scholar
• Gracie DJ, Williams CJM, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am. J. Gastroenterol. 2016;111(4):1–11.
   PubMed Web of Science ®Google Scholar
• Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohnʼs disease. Inflamm. Bowel Dis. 2016 Mar;22(3):623–630.
   PubMed Web of Science ®Google Scholar
• Koulaouzidis A, Sipponen T, Nemeth A, et al. Association between fecal calprotectin levels and small-bowel inflammation score in capsule endoscopy: a multicenter retrospective study. Dig. Dis. Sci. 2016;61(7):2033–2040.
   PubMed Web of Science ®Google Scholar
• Bar-Gil Shitrit A, Koslowsky B, Livovsky DM, et al. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn’s disease in patients undergoing capsule endoscopy. Scand. J. Gastroenterol. 2016;0(0):1–6.
   Google Scholar
• Boon GJ, Day AS, Mulder CJ, et al. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?. World J Gastroenterol. 2015 Oct;21(40):11469–11480.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho K-L, et al. Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohnʼs disease activity index and endoscopic findings. Inflamm. Bowel Dis. 2008 Jan;14(1):40–46.
   PubMed Web of Science ®Google Scholar
• García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis. J Crohns Colitis. 2010;4:144–152.
   Google Scholar
• Scaioli E, Digby RJ, Belluzzi A. Different cutoff levels of fecal calprotectin to predict clinical relapse in ulcerative colitis. Inflamm. Bowel Dis. 2016;22(7):2016.
   PubMed Web of Science ®Google Scholar
• Mao R, Xiao Y, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: ameta-analysis of prospective studies. Inflamm. Bowel Dis. 2012 Oct;18(10):1894–1899.
   PubMed Web of Science ®Google Scholar
• DʼHaens G, Ferrante M, Vermeire S, et al. “Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease”. Inflamm. Bowel Dis. 2012 Dec;18(12):2218–2224.
   PubMed Web of Science ®Google Scholar
• Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?. J Crohn’s Colitis. 2015 Jan;9(4):33-40.
   Google Scholar
• Gisbert JP, Bermejo F, Pérez-Calle J-L, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis. 2009 Aug;15(8):1190–1198.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Björkesten C-GA, Färkkilä M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand. J. Gastroenterol. 2010 Mar;45(3):325–331.
   PubMed Web of Science ®Google Scholar
• Lasson A, Hman L, Stotzer P-O, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United Eur. Gastroenterol. J. 2015;3(1):72–79.
   PubMed Web of Science ®Google Scholar
• Wagner M, Peterson CGB, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J. Gastroenterol. 2008;14(36):5584–5589.
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am. J. Gastroenterol.. 2009 Mar;104(3):673–678.
   PubMed Web of Science ®Google Scholar
• Huang VW, Prosser C, Kroeker KI, et al. Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy. Inflamm Bowel Dis. 2016;21(6):1359–1367.
   Web of Science ®Google Scholar
• De Vos M, Dewit O, D’Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J. Crohn’s Colitis. 2012 Jun;6(5):557–562.
   Google Scholar
• Molander P, af Björkesten C-G, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm. Bowel Dis. 2012 Nov;18(11):2011–2017.
   PubMed Web of Science ®Google Scholar
• Magro F, Lopes S, Lopes J, et al. Histological outcomes and predictive value of faecal markers in moderately to severely active ulcerative colitis patients receiving infliximab. J. Crohn’s Colitis. 2016 Dec;10(12):1407–1416.
   Google Scholar
• Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment. Pharmacol. Ther. 2011;34(4):462–469.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment. Pharmacol. Ther. 2016 Dec 44(11–12):1199-1212.
   PubMed Web of Science ®Google Scholar
• Hashiguchi K, Takeshima F, Akazawa Y, et al. Advantages of fecal lactoferrin measurement during granulocyte and monocyte adsorptive apheresis therapy in ulcerative colitis. Digestion. 2015 Mar;91(3):208–217.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet (London, England). 1991 Sep;338(8770):771–774.
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Diagnosis and monitoring of postoperative recurrence in Crohn’s disease. Expert Rev. Gastroenterol. Hepatol. 2015 Jan;9(1):55–66.
   PubMed Web of Science ®Google Scholar
• Nguyen V, Kanth R, Gazo J, et al. Management of post-operative Crohn’s disease in 2017: where do we go from here? Expert Rev. Gastroenterol. Hepatol. 2016 Nov;10(11):1257–1269.
   PubMed Web of Science ®Google Scholar
• Beltran B, Cerrillo E, Iborra M, et al. Fecal calprotectin (FC) is a useful early predictive marker for postoperative recurrence in crohn’s disease (CD). Gastroenterology. 2012;142(5):S659.
   Web of Science ®Google Scholar
• Herranz MT, Ruiz-Zorrilla R, Alcaide N, et al. Is faecal calprotectin a useful marker of postoperative recurrence in Crohn’s ileal disease?. J. Crohn’s Colitis. 2012;6: S63.
   Google Scholar
• Kamm MA, De Cruz PP, Wright EK, et al. OP023 optimising post-operative Crohn’s disease management: best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. J. Crohn’s Colitis. 2014;8(Supplement 1):S13.
   Google Scholar
• Laidet M, Boschetti G, Phelip G, et al. Early measurement of fecal calprotectin after intestinal resection is useful to predict postoperative recurrence in patients with Crohn’s disease. J. Crohn’s Colitis. 2014;8: S159.
   Google Scholar
• Lasson A, Strid H, Öhman L, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease - A comparison with findings at ileocolonoscopy. J. Crohn’s Colitis. 2014;8(8):789–795.
   Google Scholar
• Orlando A,Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: A comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10(1):17–22.
   PubMedGoogle Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of crohn’s disease after surgery. Gastroenterology. 2015;148:938–947.e1.
   PubMed Web of Science ®Google Scholar
• Herranz Bachiller MT, Barrio Andres J, Fernandez Salazar L, et al. The utility of faecal calprotectin to predict post- operative recurrence in Crohńs disease. Scand. J. Gastroenterol. 2016;51(6):720–726.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United Eur. Gastroenterol. J. 2013;1(5):368–374.
   PubMed Web of Science ®Google Scholar
• Garcia-Planella E, Mañosa M, Cabré E. fecal calprotectin levels are closely correlated with the absence of relevant mucosal lesions in postoperative crohn ’ s disease. Inflamm Bowel Dis. 2016 Dec;22(12):2879-2885.
   Google Scholar
• Benitez J-M, Meuwis M-A, Reenaers C, et al. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring.. Gut. 2013;62(12):1806–1816.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Maestranzi S, Duffy AM, et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur. J. Gastroenterol. Hepatol. 2008 Mar;20(3):174–179.
   PubMed Web of Science ®Google Scholar
• Oord T, Hornung N. Fecal calprotectin in healthy children. Scand. J. Clin. Lab. Invest. 2014 Apr;74(3):254–258.
   PubMed Web of Science ®Google Scholar
• Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2014 May;109(5):637–645.
   PubMed Web of Science ®Google Scholar
• Hoekman DR, Diederen K, Koot BGP, et al. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr. 2016 Oct;175(10):1335-1342.
   Web of Science ®Google Scholar
• Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig. Dis. Sci. 2011 Aug;56(8):2372–2377.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J. Pediatr. Gastroenterol. Nutr. 2005 Apr;40(4):450–455.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho K-L. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand. J. Gastroenterol. 2010 Aug;45(7–8):872–877.
   PubMed Web of Science ®Google Scholar
• Berni Canani R, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis. 2008;40(7):547–553.
   PubMedGoogle Scholar
• Merras-Salmio L, Kolho K-L. Clinical use of infliximab trough levels and antibodies to infliximab in pediatric inflammatory bowel disease patients. J. Pediatr. Gastroenterol. Nutr. 2017 Feb;64(2):272-278.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn MD, Boone JH, Nguyen JT, et al. Utility of fecal lactoferrin in identifying crohn disease activity in children. J. Pediatr. Gastroenterol. Nutr. 2010 Oct;51(4):425–428.
   PubMed Web of Science ®Google Scholar
• Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007;44(1):414–422.
   PubMed Web of Science ®Google Scholar